Select publications

Czuczman MS et al. Interim results from a phase I/II study of anti-CD80 antibody (IDEC-114) therapy for follicular NHL. Proc ASCO 2003;Abstract 2310.

Dreyling M et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005;105(7):2677-84. Abstract

Forstpointner R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104(10):3064-71. Abstract

Ghielmini M et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23(4):705-11. Abstract

Goy A et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2005;23(4):667-75. Abstract

Hainsworth JD et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma — A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6):1088-95. Abstract

Hiddemann W et al. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) on the remission rate and time to treatment failure compared to CHOP alone in mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Proc ASCO 2004;Abstract 6501.

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Lenz G et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23(9):1984-92. Abstract

Leonard J. Results from a phase I/II study of galiximab (anti-cd80) in combination with rituximab (anti-cd20) for relapsed or refractory, follicular NHL. Presentation. Ninth International Conference on Malignant Lymphoma 2005. No abstract available

List A et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549-57. Abstract

Marcus R et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23. Abstract

O’Connor OA et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23(4):676-84. Abstract

Romaguera JE et al. Rituximab plus hypercvad (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A) in untreated mantle cell lymphoma (MCL): Prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS). Proc ASH 2004;Abstract 128.

van Oers MH et al. Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera®) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: A phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.